CONFIDENTIAL TREATMENT REQUESTED EXHIBIT 10.68
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL
TREATMENT IS REQUESTED IS OMITTED AND IS NOTED WITH "[CONFIDENTIAL TREATMENT
REQUESTED]." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
THIRD AMENDMENT TO AGREEMENT
THIS THIRD AMENDMENT TO AGREEMENT ("Third Amendment") is made and effective as of this 12th
day of November, 2001, by and between MDS (CANADA) INC., MDS NORDION division, successor to
MDS NORDION INC. ("Nordion"), and IDEC PHARMACEUTICALS CORPORATION ("IDEC").
A. Nordion and IDEC are parties to that certain Agreement dated May 14, 1999, whereby Nordion agreed to
manufacture and supply Isotope for use with IDEC's Labelled Drug ("Isotope Agreement").
B. The Isotope Agreement was subsequently amended by a letter agreement between the parties dated January
25, 2000 (`First Amendment"), a letter agreement between the parties dated March 21, 2000 relating to Isotope
dose size ("Isotope Dose Size Letter") and a Letter Agreement between the parties dated March 22, 2001
("Second Amendment"). The Isotope Agreement, as amended by the First Amendment, Isotope Dose Size
Letter and Second Amendment are collectively referred to herein as the "Agreement."
C. Nordion and IDEC desire to further amend the Agreement as set forth in this Third Amendment.
D. Unless otherwise defined herein, capitalized items as used herein shall have the meanings as given thereto in
NOW THEREFORE, in consideration of the mutual covenants and agreements herein contained, and subject to
the terms and conditions hereinafter set out, the parties agree as follows:
1. INCREASED DOSE SIZE, PRICE AND REPORTING.
1.1 Section 6.2 of the Agreement relating to production planning for Clinical Trial and Pre-Commercial Phase
supply is amended to provide that Isotope may be shipped in as many as [CONFIDENTIAL TREATMENT
REQUESTED] sizes to be discussed by the parties and